Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.10.0.1
Strategic Alliances (Details) - USD ($)
1 Months Ended 6 Months Ended 9 Months Ended 26 Months Ended 42 Months Ended 91 Months Ended
Oct. 12, 2017
May 31, 2016
Jan. 31, 2015
Dec. 31, 2010
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2018
Dec. 31, 2017
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Upfront payment from development and license agreement $ 6,000,000                      
Milestone revenue recognized             $ 0          
Contract liability         $ 109,600,000   109,600,000 $ 109,600,000 $ 109,600,000 $ 109,600,000 $ 140,400,000  
Contract liabilities         61,846,000   61,846,000 61,846,000 61,846,000 61,846,000 61,388,000  
Contract liabilities         47,720,000   47,720,000 47,720,000 47,720,000 47,720,000 $ 78,990,000  
VFMCRP                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Milestone revenue recognized               0        
VFMCRP | Development and License Agreement                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
License revenue, initial payment   $ 50,000,000                    
VFMCRP | Regulatory Milestones                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Additional milestone payment to be received   37,000,000                    
VFMCRP | Launch and Sales-based Milestones                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Additional milestone payment to be received   195,000,000                    
VFMCRP | Exclusive Option                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Additional milestone payment to be received   $ 555,000,000                    
Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Milestone revenue recognized                 0      
Additional milestone payment to be received     $ 275,000,000.0                  
Non-refundable and non-creditable upfront payment     295,000,000                  
Contract liability         100,100,000   100,100,000 100,100,000 100,100,000 100,100,000    
Tesaro                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Milestone revenue recognized         0 $ 0            
Upfront payment under license agreements       $ 6,000,000.0                
Milestone payment received                   30,000,000    
Additional milestone payment       $ 85,000,000                
Period from first commercial sale       12 years                
Written termination threshold       3 months                
Accrued Expenses | Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Contract liabilities         58,800,000   58,800,000 58,800,000 58,800,000 58,800,000    
Other Noncurrent Liabilities | Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Contract liabilities         $ 41,300,000   $ 41,300,000 $ 41,300,000 $ 41,300,000 $ 41,300,000    
Minimum | Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Each milestone payment     20,000,000.0                  
Maximum | Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Each milestone payment     $ 90,000,000.0                  
Pharmsynthez                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Ownership percentage, equity method         9.00%   9.00% 9.00% 9.00% 9.00%    
Rxi Pharmaceuticals Corporation                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Maximum milestone payments to be received                       $ 50,000,000.0
Phase Two Initiation                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Milestone payment from development and license agreement 6,000,000                      
Regulatory And Development                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Milestone payment from development and license agreement 31,000,000                      
Sales Revenue                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Milestone payment from development and license agreement $ 75,000,000